Poststroke Spasticity, Seen Too Late
New guidance from the American Heart Association addresses delayed recognition of poststroke spasticity and outlines opportunities to improve timing of rehabilitation care.
By
Kathryn Wighton
February 9, 2026
Clinical Scorecard: Poststroke Spasticity, Seen Too Late
At a Glance
Category Detail
Condition Poststroke Spasticity Key Mechanisms Abnormal muscle activation, impaired voluntary motor control, structural tissue changes. Target Population Stroke survivors, particularly those with severe motor weakness, early hyperreflexia, or lesions involving the internal capsule or brainstem. Care Setting Primary care, inpatient settings, and specialized spasticity management clinics.
Key Highlights
Affects 30% to 80% of stroke survivors in the US. Early intervention within the first 3 months post-stroke is critical. Botulinum toxin shows strong evidence for reducing involuntary muscle activation. Cost of care is four times higher when spasticity is present. Improving clinician education and referral pathways is essential. Guideline-Based Recommendations
Diagnosis
Utilize the Modified Ashworth Scale for assessment. Develop validated screening approaches for nonspecialists. Management
Early administration of botulinum toxin. Incorporate task-specific training and functional electrical stimulation. Monitoring & Follow-up
Regular assessment of muscle activation and functional gains. Risks
Patients may experience pain, loss of joint flexibility, skin complications, and fixed contractures. Patient & Prescribing Data
Stroke survivors at risk for developing spasticity.
Early mobilization within 24 to 72 hours post-stroke may help preserve muscle length and joint range of motion.
Clinical Best Practices
Educate clinicians on early signs of spasticity. Establish clearer assessment and referral pathways. Expand the workforce trained in spasticity management. Utilize telehealth and remote assessment tools to improve access. References
